PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29848078-4 2018 In silico molecular docking was applied to analyze the change in the CYP3A4-alprazolam-binding conformation when ethanol was coadministered with alprazolam. Alprazolam 76-86 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 32112986-0 2020 Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Alprazolam 99-109 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 57-63 32112986-3 2020 Results of the previous studies have shown that CYP3A is involved in the biotransformation of alprazolam, the activity of which is dependent, inter alia, on the polymorphism of the encoding gene. Alprazolam 94-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 48-53 32112986-4 2020 OBJECTIVE: The objective of our study was to investigate the effect of 99366316G>A polymorphism of the CYP3A4 gene on the concentration/dose indicator of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder, using findings on enzymatic activity of CYP3A (as evaluated by the 6-beta-hydroxy-cortisol/cortisol ratio measurement) and on CYP3A4 expression level obtained by measuring the miR-27b plasma concentration levels in patients with anxiety disorders comorbid with alcoholism. Alprazolam 154-164 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 32112986-4 2020 OBJECTIVE: The objective of our study was to investigate the effect of 99366316G>A polymorphism of the CYP3A4 gene on the concentration/dose indicator of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder, using findings on enzymatic activity of CYP3A (as evaluated by the 6-beta-hydroxy-cortisol/cortisol ratio measurement) and on CYP3A4 expression level obtained by measuring the miR-27b plasma concentration levels in patients with anxiety disorders comorbid with alcoholism. Alprazolam 154-164 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-108 32112986-4 2020 OBJECTIVE: The objective of our study was to investigate the effect of 99366316G>A polymorphism of the CYP3A4 gene on the concentration/dose indicator of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder, using findings on enzymatic activity of CYP3A (as evaluated by the 6-beta-hydroxy-cortisol/cortisol ratio measurement) and on CYP3A4 expression level obtained by measuring the miR-27b plasma concentration levels in patients with anxiety disorders comorbid with alcoholism. Alprazolam 154-164 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 362-368 32112986-19 2020 CONCLUSION: The effect of genetic polymorphism of the CYP3A4 gene on the efficacy and safety profiles of alprazolam was demonstrated in a group of 105 patients with anxiety disorders comorbid with alcohol use disorder. Alprazolam 105-115 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 54-60 29848078-4 2018 In silico molecular docking was applied to analyze the change in the CYP3A4-alprazolam-binding conformation when ethanol was coadministered with alprazolam. Alprazolam 145-155 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 29848078-7 2018 Molecular docking results suggested that the conformation of CYP3A4 with alprazolam changed when ethanol was bound to the SER119 residue, which seems critical in the process of CYP3A4-alprazolam binding. Alprazolam 73-83 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 29848078-7 2018 Molecular docking results suggested that the conformation of CYP3A4 with alprazolam changed when ethanol was bound to the SER119 residue, which seems critical in the process of CYP3A4-alprazolam binding. Alprazolam 73-83 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 177-183 29848078-7 2018 Molecular docking results suggested that the conformation of CYP3A4 with alprazolam changed when ethanol was bound to the SER119 residue, which seems critical in the process of CYP3A4-alprazolam binding. Alprazolam 184-194 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 29848078-7 2018 Molecular docking results suggested that the conformation of CYP3A4 with alprazolam changed when ethanol was bound to the SER119 residue, which seems critical in the process of CYP3A4-alprazolam binding. Alprazolam 184-194 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 177-183 29848078-8 2018 CONCLUSIONS: Ethanol might increase the toxicity of alprazolam by inhibiting the activity of CYP3A4, although other pharmacokinetic processes may be affected. Alprazolam 52-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 93-99 29848078-9 2018 Ethanol could change the conformation of CYP3A4 and affect alprazolam binding. Alprazolam 59-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-47 22159869-0 2012 Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. Alprazolam 14-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 26315684-0 2015 Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. Alprazolam 114-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-39 26315684-9 2015 Co-administration with levomilnacipran of drugs metabolised by CYP3A4, such as alprazolam, requires no dose adjustment due to pharmacokinetic considerations. Alprazolam 79-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 22159869-1 2012 OBJECTIVE: To investigate the impact of persistent inflammation in hemodialysis (HD) patients on the pharmacokinetics of alprazolam, a cytochrome P450 (CYP) 3A4 substrate, and its metabolites and the role of HD in the impact of persistent inflammation in this clinical context. Alprazolam 121-131 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-160 22159869-5 2012 CYP3A4 activity was estimated as the ratio of unconjugated alprazolam to 4-hydroxyalprazolam between 10 and 34 h following alprazolam intake. Alprazolam 59-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 20501911-3 2010 The kinetics of metabolite formation from phenacetin, tolbutamide, and alprazolam and midazolam, selected as substrates probes for CYP1A2, CYP2C9, and CYP3A4, respectively, were characterized in this in vitro system. Alprazolam 71-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 151-157 22159869-5 2012 CYP3A4 activity was estimated as the ratio of unconjugated alprazolam to 4-hydroxyalprazolam between 10 and 34 h following alprazolam intake. Alprazolam 82-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 22159869-11 2012 CONCLUSIONS: The correlation between CYP3A4 activity (assessed by alprazolam 4-hydroxylation) and CRP level suggests that inflammation may downregulate CYP3A4 activity. Alprazolam 66-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-43 22159869-11 2012 CONCLUSIONS: The correlation between CYP3A4 activity (assessed by alprazolam 4-hydroxylation) and CRP level suggests that inflammation may downregulate CYP3A4 activity. Alprazolam 66-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 152-158 17979656-7 2007 The maximal F(G) ratios for the 11 CYP3A4 substrates investigated ranged from 1.06-7.14 for alprazolam and tacrolimus, respectively. Alprazolam 92-102 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 20080160-9 2010 In conclusion, Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Lorazepam, Nitrazepam, Oxazepam, Tetrazepam and Triazolam can be considered as safe drugs in term of their inability to induce PXR- and AhR-dependent cytochrome P450 enzymes CYP1A2 and CYP3A4. Alprazolam 15-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 264-270 17200836-12 2007 Alprazolam metabolism (both alpha- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ 2S,4R, with IC(50) values of 0.03 microM. Alprazolam 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-77 17639026-1 2007 Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors (PIs) can be explained by their propensity to inactivate CYP3A enzymes, paradoxically these drugs cause (or lack) interactions with CYP3A substrates that cannot be explained by this mechanism (e.g., alprazolam). Alprazolam 328-338 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 186-191 17200836-13 2007 CONCLUSIONS: Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. Alprazolam 13-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 17200836-0 2007 Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Alprazolam 56-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 14586385-0 2003 Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. Alprazolam 131-141 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-19 15903124-10 2005 Determination of the alprazolam 1-hydroxylation rate revealed that CYP3A5 plays a significant role in the metabolism of CYP3A substrates in the fetal liver. Alprazolam 21-31 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 67-72 15806426-0 2005 Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Alprazolam 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 26-31 15806426-1 2005 OBJECTIVES: (1) To determine the pharmacokinetic parameters of alprazolam and its two metabolites in plasma from healthy volunteers; (2) to identify a suitable single time point to take a plasma sample for CYP3A phenotyping. Alprazolam 63-73 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 206-211 14709940-5 2004 CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ. Alprazolam 165-175 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 16791582-0 2006 Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. Alprazolam 107-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 89-95 15342470-8 2004 The differences observed in the benzodiazepine metabolite pathway ratios between CYP3A4 and CYP3A5, particularly for 1"- to 4-hydroxymidazolam and alprazolam, provided a useful measure of interindividual differences within the CYP3A family. Alprazolam 147-157 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 11745908-0 2001 In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Alprazolam 28-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 13129991-7 2003 MAIN OUTCOME MEASURES: Changes in plasma pharmacokinetics of alprazolam as a probe for CYP 3A4 activity and the ratio of dextromethorphan to its metabolite, dextrorphan, in urine as a probe for CYP 2D6 activity. Alprazolam 61-71 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 87-94 13129991-11 2003 CONCLUSIONS: A 14-day course of St John"s wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. Alprazolam 134-144 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-107 24930414-6 2003 Although there is insufficient evidence, a substantial inhibition of CYP 3A3/4 by venlafaxine could result in a meaningful increase in plasma levels of venlafaxine, O-desmethylvenlafaxine, alprazolam and diazepam, particularly in patients who are CYP 2D6 deficient. Alprazolam 189-199 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-76 11304902-4 2001 Alprazolam is extensively metabolized by CYP3A4. Alprazolam 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-47 12920410-1 2003 The selective serotonin reuptake inhibitor antidepressant fluoxetine inhibits alprazolam metabolism in vivo by inhibition of the cytochrome P450 3A4 enzyme. Alprazolam 78-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-148 11549205-2 2001 We investigated the correlation between this ratio and the disposition of alprazolam, which is a substrate of CYP3A4. Alprazolam 74-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 110-116 11745908-10 2001 In conclusion, we have succeeded in carrying out an in vitro/in vivo scaling of alprazolam metabolism using human liver microsomes and human CYP3A4 and CYP3A5 recombinants. Alprazolam 80-90 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-147 10801241-3 2000 METHODS: The inhibitory effect of ritonavir on the metabolism of alprazolam, a CYP3A-mediated reaction in humans, was tested in vitro using human liver microsomes. Alprazolam 65-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 79-84 10634135-0 1999 Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Alprazolam 67-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 10664927-0 2000 Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. Alprazolam 49-59 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-36 10770452-1 2000 In vitro data show the inhibition of alprazolam metabolism by sertraline via CYP3A4; therefore, using a randomized, double-blind, placebo-controlled design, the authors conducted this study to assess the potential for similar in vivo inhibition in humans. Alprazolam 37-47 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 10688619-5 2000 The capacity of ketoconazole, a CYP3A inhibitor in humans, to inhibit the biotransformation of MDZ and of alprazolam, another human CYP3A substrate, did not differ significantly with age. Alprazolam 106-116 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 132-137 10634135-1 1999 Alprazolam (ALP) and caffeine (CAF) were suggested as probe drugs for the activities of CYP3A4 and CYP1A2, respectively. Alprazolam 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 10634135-1 1999 Alprazolam (ALP) and caffeine (CAF) were suggested as probe drugs for the activities of CYP3A4 and CYP1A2, respectively. Alprazolam 12-15 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 9784084-6 1998 It is suggested that itraconazole, a potent CYP3A4 inhibitor, increases plasma concentration of alprazolam via its inhibitory effects on alprazolam metabolism. Alprazolam 96-106 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 10548453-4 1999 The formation of 4-hydroxyalprazolam and 1"-hydroxyalprazolam at an alprazolam concentration of 62.5 microM were reduced by the prototypic CYP3A inhibitor, troleandomycin (50 microM), by 97 and 9900 respectively. Alprazolam 26-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 139-144 10548453-5 1999 Only microsomes from B-lymphoblastoid cells expressing CYP3A4 were capable of catalysing the 1"- and 4-hydroxylation of alprazolam. Alprazolam 120-130 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 10548453-8 1999 A significant (p<0.01) correlation was observed between alprazolam 4- and 1"-hydroxylase activity and CYP3A-mediated midazolam 4-hydroxylase, midazolam 1"-hydroxylase, dextromethorphan N-demethylase and erythromycin N-demethylase activities. Alprazolam 59-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-110 10548453-10 1999 In conclusion, in adult human liver the CYP3A subfamily members are the principal enzymes involved in the 1"- and 4-hydroxylation of alprazolam. Alprazolam 133-143 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 40-45 10548453-11 1999 Thus, clinically significant drug drug interactions between alprazolam and other CYP3A substrates are to be expected. Alprazolam 60-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-86 9784084-6 1998 It is suggested that itraconazole, a potent CYP3A4 inhibitor, increases plasma concentration of alprazolam via its inhibitory effects on alprazolam metabolism. Alprazolam 137-147 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 9784084-7 1998 Thus, this study supports previous studies suggesting that CYP3A4 is the major enzyme catalyzing the metabolism of alprazolam. Alprazolam 115-125 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 9098872-8 1997 CONCLUSIONS: Since alprazolam has been suggested to be mainly metabolized by the CYP3A4 isozyme in humans, it appears that tobacco could be an inducer of CYP3A4 and/or alprazolam may be metabolized by other isozyme(s) (specifically, CYP1A1/1A2) that are induced by cigarette smoke. Alprazolam 19-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 9498726-6 1998 Although both sertindole and alprazolam are substrate for CYP3A4 (cytochrome P-450 3A4), the results in this study suggest that sertindole is not an inhibitor of the metabolism of alprazolam. Alprazolam 29-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-64 9498726-6 1998 Although both sertindole and alprazolam are substrate for CYP3A4 (cytochrome P-450 3A4), the results in this study suggest that sertindole is not an inhibitor of the metabolism of alprazolam. Alprazolam 29-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 66-86 9641003-1 1998 Potential pharmacokinetic effects of venlafaxine on alprazolam, a substrate of the cytochrome pigment 450 (CYP) isoenzyme CYP3A4, were investigated in 16 healthy volunteers. Alprazolam 52-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 122-128 9536449-1 1998 The effect of carbamazepine, an inducer of cytochrome P450 (CYP) 3A4, on the single oral dose pharmacokinetics of alprazolam was examined in a double-blind, randomized crossover study with two phases. Alprazolam 114-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-68 9536449-8 1998 It also supports the previous studies, suggesting that alprazolam is metabolized predominantly by CYP3A4. Alprazolam 55-65 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 9098872-8 1997 CONCLUSIONS: Since alprazolam has been suggested to be mainly metabolized by the CYP3A4 isozyme in humans, it appears that tobacco could be an inducer of CYP3A4 and/or alprazolam may be metabolized by other isozyme(s) (specifically, CYP1A1/1A2) that are induced by cigarette smoke. Alprazolam 19-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 154-160 9098872-8 1997 CONCLUSIONS: Since alprazolam has been suggested to be mainly metabolized by the CYP3A4 isozyme in humans, it appears that tobacco could be an inducer of CYP3A4 and/or alprazolam may be metabolized by other isozyme(s) (specifically, CYP1A1/1A2) that are induced by cigarette smoke. Alprazolam 168-178 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 8968657-16 1996 Interactions observed between fluoxetine and alprazolam, midazolam and carbamazepine seem to occur on the level of CYP3A. Alprazolam 45-55 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 115-120 8905799-0 1996 [The relationship between single-oral dose kinetics of alprazolam and cytochrome P4503A and cytochrome P4502C19]. Alprazolam 55-65 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 70-76 8905799-1 1996 To clarify the involvement of cytochrome P4503A (CYP3A) and CYP2C19 in the metabolism of alprazolam, the effects of pretreatment with erythromycin, which is an inhibitor of CYP3A and S-mephenytoin 4-hydroxylation capacity on the single-oral dose kinetics of alprazolam were studied in 12 healthy male volunteers. Alprazolam 89-99 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 8905799-1 1996 To clarify the involvement of cytochrome P4503A (CYP3A) and CYP2C19 in the metabolism of alprazolam, the effects of pretreatment with erythromycin, which is an inhibitor of CYP3A and S-mephenytoin 4-hydroxylation capacity on the single-oral dose kinetics of alprazolam were studied in 12 healthy male volunteers. Alprazolam 89-99 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-54 8905799-8 1996 The present study thus suggests that CYP3A, but not CYP2C19, is involved in the metabolism of alprazolam. Alprazolam 94-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-42 8610817-8 1996 Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines. Alprazolam 72-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-19 8748566-11 1995 Nefazodone, an inhibitor of the hepatic P-450 isoenzyme CYP3A4, may increase concentrations of drugs metabolized by this isoenzyme, such as terfenadine, astemizole, triazolam, alprazolam, and midazolam. Alprazolam 176-186 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 8646822-0 1996 A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Alprazolam 138-148 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 128-134 8646822-1 1996 OBJECTIVE: To assess the possible involvement of CYP3A4 in the metabolism of alprazolam in vivo. Alprazolam 77-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-55 8646822-9 1996 CONCLUSION: This study suggests that erythromycin, an inhibitor of CYP3A4, inhibits the metabolism of alprazolam, providing an in vivo evidence for the involvement of CYP3A4 in its metabolism. Alprazolam 102-112 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 67-73 8646822-9 1996 CONCLUSION: This study suggests that erythromycin, an inhibitor of CYP3A4, inhibits the metabolism of alprazolam, providing an in vivo evidence for the involvement of CYP3A4 in its metabolism. Alprazolam 102-112 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 167-173 8748428-9 1995 Competitive inhibition between alprazolam and nefazodone metabolism at cytochrome P450 3A4 may be responsible for the pharmacokinetic interaction when alprazolam and nefazodone were coadministered. Alprazolam 31-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-90 8748428-9 1995 Competitive inhibition between alprazolam and nefazodone metabolism at cytochrome P450 3A4 may be responsible for the pharmacokinetic interaction when alprazolam and nefazodone were coadministered. Alprazolam 151-161 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-90 35351776-13 2022 The canine CYP2B11 was found to appreciably contribute to hydroxylation of midazolam, alprazolam and triazolam, the well-known probes for human CYP3A. Alprazolam 86-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 144-149